CLOs on the Move

QualCare Inc.

www.qualcareinc.com

 
QualCare, Inc., one of the region`s leading providers of health care coverage, provides the public and private marketplace with a higher-quality, lower-cost alternative to commercial insurance companies. QualCare`s network covers over 100 acute, specialty and rehabilitation hospitals, as well as over 31,000 physicians and other ancillary providers across New Jersey, New York and Pennsylvania. Founded in 1991 from a consortium of hospital systems, QualCare has experienced dramatic growth over the past two decades. Currently, 16 of New Jersey`s largest and most successful hospitals own and serve on QualCare`s Board of Directors. QualCare services over 900,000 members, with a clientele that spans health ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Nodality

Nodality is an innovative personalized medicine company focused on improving the efficiency of drug development for therapeutics as well as generating highly predictive companion diagnostics to improve patient care.

Access Pro Medical

Access Pro Medical is a supplier of burn and advanced wound care supplies to healthcare facilities.

Rural Health

Rural Health Inc. is a Anna, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medsphere

Medsphere is leading a revolution in healthcare information technology applications, significantly and positively impacting the way healthcare institutions enhance patient safety, improve clinical efficiency and increase healthcare quality.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.